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Neutrophil functions are impaired in patients with dia-
betes mellitus. Bacterial phagocytosis and oxidative burst
activity are reduced at high glucose concentrations in dia-
beticpatients.Defectsinneutrophiloxidativeburstcapacity
are of multifactorial origin in diabetes mellitus and corre-
latewithglucoselevels.Ithasbeenreportedthatneutrophil
NADPH oxidase activity is impaired and superoxide pro-
duction is reduced in diabetic patients with or without any
infections. Nicotinamide is a vitamin B3 derivative and a
NAD precursor with immunomodulatory effects. In vitro
studiesdemonstratedthatnicotinamideincreasesNADand
NADH content of beta cells. The authors hypothesized that
nicotinamide may restore the impaired oxidative burst ca-
pacity of neutrophils in diabetic patients by increasing the
NADH content as an electron donor and possibly through
NADPH oxidase activity of the cell. In order to test the hy-
pothesis, this placebo-controlled and open study was de-
signed to evaluate neutrophil functions in infection-free
poorly controlled type 2 diabetic patients as compared to
healthy subjects and assess the effects of nicotinamide on
neutrophil phagocytosis as well as oxidative burst activ-
ity. Thirty patients with type 2 diabetes mellitus were en-
rolled in the study. Sixteen were females and 14 were males,
with a mean age 58±10. All patients were on sulphony-
lurea treatment and their hemoglobin A1c (HbA1c) levels
were above 7.5%. The control group consisted of 10 volun-
tary healthy subjects. Diabetic and control subjects were
Received 15 January 2003; accepted 15 September 2003.
This study is supported by Istanbul University Research Fund.
AddresscorrespondencetoZeynepOsar,HavaciFeyzaSok.P26/9,
Atak¨ oy 3. Kisim, Bakirk¨ oy, Istanbul, Turkey. E-mail: zeyneposar@
yahoo.com
not signiﬁcantly different in terms of age, body mass in-
dex (BMI), leucocyte and neutrophil counts, C-reactive
protein (CRP) level, and erythrocyte sedimentation rate
(ESR), but HbA1c and fasting glucose levels were signif-
icantly higher in patients with diabetes mellitus. Phago-
cytic activity and respiratory burst indexes were measured
by ﬂow cytometric analyses as previously described by
Rothe and Valet (Methods Enzyml., 233, 539–548, 1994) and
compared in diabetic subjects and healthy controls. Dia-
betic patients were grouped to receive either 50 mg/kg oral
nicotinamide (n=15) or placebo (n=15) for a period of
1 month. The 2 groups did not differ in terms of treatment,
frequency of hypertension, BMI, diabetes duration, age,
fasting plasma glucose (FPG), HbA1c, CRP, ESR, polymor-
phonuclear leukocyte (PNL) and neutrophil counts. Neu-
trophil functions were reassessed after the treatment pe-
riod. Phagocytic activity represented as indexes were lower
in diabetic patients when compared to healthy subjects, but
the differences were not statistically signiﬁcant (P>.05).
Patients with diabetes mellitus had signiﬁcantly lower ox-
idative burst indexes when compared to healthy controls
(P values < .05). In diabetic patients, a negative correlation
between neutrophil functions and HbA1c was found which
was not statistically signiﬁcant (P values > .05). Phagocytic
indexes were similar in nicotinamide and placebo groups
after treatment period (P > .05). But oxidative burst ac-
tivity in patients receiving nicotinamide was greater when
compared with placebo and the difference was statistically
signiﬁcant at 30 and 45 minutes (P values .04 and .03). This
effect of nicotinamide may be due to increased NADH con-
tent and NADPH oxidase activity of the cell, which needs to
be further studied. Impaired neutrophil functions may ag-
gravate various infections in patients with diabetes mellitus
andbloodglucoseregulationisanimportanttargetoftreat-
ment to improve neutrophil functions. But nicotinamide
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treatment may help to improve prognosis in diabetic pa-
tients with severe infections.
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In diabetic patients, polymorphonuclear leukocyte (PNL)
functions are altered at different steps. Impaired chemotaxis,
defective phagocytosis, and increased production of free rad-
icals have been reported to occur in diabetes mellitus (DM)
[1–3]. PNL oxidative burst activity and bacterial ingestion and
killing are reduced at high glucose concentrations in diabetic
patients [4]. These derrangements in neutrophil functions may
increase the risk of infection in DM.
The oxidative burst is an important step in bacterial killing
and involves a series of metabolic events that take place when
phagocytes are stimulated, resulting in the production of super-
oxide (O
−
2 ), H2O2, and other more potent oxidizing radicals.
These reactions are coupled with an increase in glucose oxida-
tion via the hexose monophosphate shunt. Most of the oxida-
tive burst is caused by activation of an NADPH oxidase that
catalyses 1-electron reduction of oxygen to superoxide, using
NAPDH as the electron donor [5]. Defects in neutrophil ox-
idative burst capacity are of multifactorial origin in diabetic pa-
tientsandcorrelateswithglucoselevels[6].DecreasedNADPH
levels in connection with reduced NADPH oxidase activity is
one of the most underlined mechanisms in the impairment of
PNL functions in DM. It has been reported that neutrophil
NADPH oxidase activity is impaired and superoxide produc-
tion is reduced in diabetic patients without any infection [6] as
well as with periodontitis [7] or foot infections [8].
Nicotinamide is a vitamin B3 derivative and a NAD precur-
sor with immunomodulatory effects. It has been proposed that
nicotinamide supresses poly(ADP-ribose)polymerase (PARP)
activity and, to a lesser extent, (mono)ADP-ribosyl tranferase
activity [9, 10]. Supression of PARP activity decreases con-
sumption of NAD, the substrate for PARP [10]. In vitro stud-
ies demonstrated that nicotinamide increases NAD and NADH
content of beta cells [11].
The physiological electron donor of respiratory burst oxi-
daseisNADPH,buttheenzymeisalsocapableofusingNADH,
though less efﬁciently [5]. We hypothesized that nicotinamide
mayrestoretheimpairedoxidativeburstcapacityofneutrophils
in diabetic patients by increasing the NADH content and possi-
bly through NADPH oxidase activity of the cell. In order to test
the hypothesis, this study was designed to evaluate neutrophil
functions in infection-free poorly controlled type 2 diabetic pa-
tients as compared to healthy subjects and assess the effects of
nicotinamide both on neutrophil phagocytosis and as oxidative
burst activity. The study is designed as a single blind study.
TABLE 1
Baseline characteristics of diabetic patients and controls
Type 2 DM Control
(mean ± SD) (mean ± SD) P value
N3 0 1 0
Gender (F/M) 16/14 5/5
Age (years) 58 ± 10 58 ± 9 .924
Duration of DM 5 ± 3 —
(years)
BMI (kg/m2)2 9 ± 52 7 ± 4 .192
FPG (mg/dL) 173 ± 34 91 ± 12 .0001∗
HbA1c (%) 8.7 ± 1.1 5.0 ± .3 .0001∗
CRP (mg/L) 2.7 ± .9 2.6 ± .6 .214
ESR (mm/h) 22 ± 11 19 ± 9 .453
PNL (/mm3) 7370 ± 1448 6900 ± 1575 .215
Neutrophil (/mm3) 4536 ± 1089 4025 ± 907 .312
∗Statistically signiﬁcant.
MATERIALS AND METHODS
Subjects
Thirty patients with type 2 DM were enrolled in the study.
Sixteen were females and 14 were males, with an age of 58 ±
10 years (mean ± SD), ranging between 44 and 75 years. The
mean duration of diabetes was 5.0 ± 3.0 years (mean ± SD)
(range 1 to 10 years). All patients were on sulphonylurea treat-
ment(gliclazideorglipizide)andtheirhemoglobinA1c (HbA1c)
levels were above 7.5%. The control group consisted of 10 vol-
untary healthy subjects. Baseline characteristics of study sub-
jects and controls were as in Table 1. There was no age and
body mass index (BMI) difference between diabetic patients
and healthy controls. Exclusion criteria were pregnancy, sys-
temic glucocorticoid treatment, systemic infection, liver func-
tion tests greater than 1.5 times of normal, serum creatinine
greater than 1.2 mg/dL, urinary albumin excretion greater than
200µg/min,proliferativediabeticretinopathy,malignancy,and
antiinﬂammatory or immunosuppressive treatment. The study
protocol was in accordance with Helsinki Declaration and ap-
provedbythelocalethicalcommittee.Allpatientsgavewritten
informed consent.
Initial Assessment
At the beginning of the study, clinical examination, leuko-
cyte and neutrophil counts, and erythrocyte sedimentation rate
(ESR), quantitative C-reactive protein (CRP), fasting plasma
glucose (FPG), and HbA1c measurements were performed.
Diabetic and control subjects were not signiﬁcantly different
in terms of PNL and neutrophil counts, CRP level, and ESR,
but HbA1c and FPG levels were signiﬁcantly higher in patientsNICOTINAMIDE AND NEUTROPHIL OXIDATIVE BURST IN DIABETES 157
TABLE 2
Baseline characteristics of diabetic patients receiving
nicotinamide and placebo
Nicotinamide Placebo
(mean ± SD) (mean ± SD) P value
N1 5 1 5
Gender (F/M) 8/7 8/7
Age (years) 55 ± 10 59 ± 8 .435
Duration of DM 5 ± 24 ± 3 .973
(years)
BMI (kg/m2)3 0 ± 52 8 ± 3 .156
FPG (mg/dL) 173 ± 30 173 ± 39 .958
HbA1c(%) 9.0 ± 1.2 8.4 ± 1.0 .136
CRP (mg/L) 2.0 ± .9 2.2 ± .6 .312
ESR (mm/h) 22 ± 11 19 ± 9 .453
PNL (/mm3) 7633 ± 1412 7106 ± 1484 .328
Neutrophil (/mm3) 4912 ± 1074 4160 ± 999 .057
with DM (Table 1). Phagocytic activity and respiratory burst
indexes were measured and compared in diabetic subjects and
healthy controls.
Nicotinamide Administration
Diabetic patients were grouped to receive either oral nicoti-
namide (n = 15) or placebo (n = 15) for a period of 1 month.
The 2 groups did not differ in terms of diabetes treatment,
frequency of hypertension, BMI, diabetes duration, age, FPG,
HbA1c, CRP, ESR, or PNL and neutrophil counts (Table 2).
Nicotinamidewasadministered50mg/kgdividedinthreedoses
taken 30 minutes before meals. Clinical examination, PNL and
FIGURE 1
Initial bacterial phagocytosis as weighted phagocytic index in patients with DM (solid line) and controls (dashed line).
neutrophil counts, and CRP, FPG, and HbA1c measurements
were repeated and neutrophil functions were reassessed after
the treatment period. Patients were questioned about possible
side effects of nicotinamide.
Biochemical and Hematological Analyses
Fasting venous plasma glucose was measured by glucose
oxidase method. HbA1c determination was based on the tur-
bidimetric inhibition immunoassay of hemolyzed whole blood
(Roche) (normal range 2.5% to 4.5%). CRP was quantitatively
measured by turbidimetric method (Behring) (normal range:
0 to 5 mg/L). ESR was measured manually in citrated whole
blood. PNL and neutrophils were counted in Beckman Coulter
Hmx Hematology Analyser.
Assessment of Neutrophil Functions
After overnight fasting, 8 mL blood sample was taken from
forearm vein into a tube containing 3 mL of density-gradient
solution(Histopaque1077,Sigma).After40minutesofgravity
separationatroomtemperature,800µLofsupernatantcontain-
ingtheleukocytepopulationwasdrawnoutwithplasticPasteur
pipette.
Phagocytosis and oxidative burst were measured by ﬂow
cytometric analyses as previously described by Rothe and
Valet [12, 13]. Three tubes were prepared for each patient:
for control, phagocytosis measurements and oxidative burst
measurements. In each tube, 1 mL buffer solution (phosphate-
buffered saline [PBS] containing 2% bovine serum albumin
[BSA]), 20 µL leukocyte suspension and 5 µL Rhodamine 123
(end concentration 1 µg/mL) (Molecular Probes, USA) were158 Z. OSAR ET AL.
FIGURE 2
Initial oxidative burst indexes in patients with DM (solid line) and controls (dashed line). ∗Statistically signiﬁcant.
mixed. Oxidative burst was stimulated with 10 µL phorbol
myristate acetate (PMA; Sigma). Staphyloccocus aureus was
used for assessment of phagocytosis. Flow cytometric analy-
ses (Coulter EPICS XL-MCL) were performed at 0, 10, 20,
30, and 45 minutes. Phagocytosis and oxidative burst indexes
were calculated by dividing the test mean channel numbers
(ﬂourescence density values) by the control mean channel
numbers.
Statistical Analyses
Independent-sample t test for between-group comparisons
and paired-sample t test for in-group comparisons were per-
formed using SPSS 10.0 for Windows. Correlations were as-
sessed using Spearman’s correlation coefﬁcient. Statistical sig-
niﬁcance was accepted as P <. 05.
RESULTS
Indiabeticsubjectsandhealthycontrols,phagocyticindexes
positively correlated with oxidative burst indexes at 20, 30, and
45 minutes (correlation coefﬁcients .35, .39, .43 and P values
.034, .036, and .021, respectively). Phagocytic activity repre-
sented as indexes were lower in diabetic patients when com-
pared to healthy subjects, but the differences were statistically
not signiﬁcant (P >. 05 at all time points) (Figure 1). Pa-
tients with DM had signiﬁcantly lower oxidative burst indexes
when compared to healthy controls at all time points (P <. 05)
(Figure 2). In diabetic patients, a negative correlation between
neutrophil functions and HbA1c was found, which was not sta-
tistically signiﬁcant (P >. 05).
FPG, HbA1c, CRP, and ESR levels as well as PNL and neu-
trophil counts were similar in nicotinamide and placebo groups
at baseline (Table 2). No signiﬁcant differences in baseline
phagocytic (Figure 3) and oxidative burst indexes (Figure 4)
were found in patients receiving nicotinamide and placebo
(P > .05).
Attheendofthetreatmentperiod,HbA1c levelsdecreasedin
bothnicotinamideandplacebogroupscomparedtobaselinebut
the differences did not reach statistical signiﬁcance (P values
.330 and .068, respectively). There were also no signiﬁcant
differences between nicotinamide and placebo groups in terms
of FPG, HbA1c, CRP, and ESR measurements, and PNL and
neutrophil counts (Table 3).
Within the nicotinamide and placebo groups, we did not ob-
serve any signiﬁcant difference when we compared phagocytic
TABLE 3
Measurements of diabetic patients after nicotinamide
treatment
Nicotinamide Placebo
(mean ± SD) (mean ± SD) P value
N1 5 1 5
BMI (kg/m2)3 0 ± 52 8 ± 3 .156
FPG (mg/dL) 168 ± 59 177 ± 55 .702
HbA1c(%) 8.4 ± 1.6 8.1 ± 1.4 .527
CRP (mg/L) 2.2 ± 1.0 2.4 ± .6 .421
ESR (mm/h) 27 ± 12 22 ± 12 .335
PNL (/mm3) 7974 ± 2623 7093 ± 1506 .269
Neutrophil (/mm3) 5243 ± 1247 4550 ± 989 .062NICOTINAMIDE AND NEUTROPHIL OXIDATIVE BURST IN DIABETES 159
FIGURE 3
Initial phagocytic index levels in nicotinamide (solid line) and placebo groups (dashed line).
and oxidative burst indexes before and after the treatment (all
P > .05). Phagocytic indexes were similar in nicotinamide and
placebo groups after treatment period (P >. 05 at all time
points) (Figure 5). Oxidative burst activity in patients receiv-
ingnicotinamidewasgreaterwhencomparedwithplacebo;the
difference, however, being statistically insigniﬁcant before the
treatment became stastistically signiﬁcant after nicotinamide
treatment at 30 and 45 minutes (P values .04 and .03, respec-
tively) (Figure 6).
FIGURE 4
Initial oxidative burst index in nicotinamide (dashed line) and placebo (solid line) groups.
As far as side effects were concerned, nausea without vom-
itting was observed in 25% of nicotinamide group, but this
symptom was limited and did not necessitate withdrawal of the
drug in any case. We did not observe any side effects in the
placebo group.
DISCUSSION
The results of our study indicate that neutrophil functions
are impaired in infection-free poorly controlled type 2 diabetic160 Z. OSAR ET AL.
FIGURE 5
Phagocytic index after treatment in nicotinamide (solid line) and placebo (dashed line) groups.
patients. Phagocytosis and respiratory burst indexes tended to
be lower in diabetic patients as compared to healthy controls,
butthedifferencewasonlystatisticallysigniﬁcantforoxidative
burstfunctions.ImpairedPMA-inducedrespiratoryburstactiv-
ity and reduced phagocytosis of S. aureus have been reported
in other studies in poorly controlled diabetic patients without
any infections [4, 6]. A study using ﬂow cytometric analyses as
in our study showed lower PMA-induced respiratory burst ac-
tivity in diabetic patients and results negatively correlated with
FIGURE 6
Oxidative burst index after treatment in nicotinamide (solid line) and placebo (dashed line) groups. ∗Signiﬁcant.
HbA1c levels [6]. In our diabetic subjects we also observed a
negative correlation between neutrophil functions and HbA1c
levels, although this was not statistically signiﬁcant.
It has been reported that neutrophil superoxide is signiﬁ-
cantly reduced during hyperglycemia in patients with type 2
DM [14]. Superoxide production is largely dependent on the
activation of membrane-bound NADPH oxidase, which is an
FAD-requiring enzyme using NADPH as the main physiolog-
ical electron donor [5]. Therefore, reduced intracellular levelsNICOTINAMIDE AND NEUTROPHIL OXIDATIVE BURST IN DIABETES 161
of NADPH results in reduction of neutrophil superoxide pro-
duction during respiratory burst [6, 7, 14]. NADPH oxidase is
also capable of using NADH as an electron donor, although in
a less efﬁcient way [5].
We hypothesized that nicotinamide, as an NAD precursor,
may restore impaired oxidative burst activity in neutrophils of
diabetic subjects. In our diabetic patients treated with nicoti-
namide, oxidative burst functions were signiﬁcantly higher at
30 and 45 minutes as compared to the placebo group, although
the difference was not signiﬁcant in the beginning and the end
of the treatment. Because both groups of patients had simi-
lar characteristics, which otherwise could potentially inﬂuence
PNL functions both at baseline and at the end of the study
period, the difference in oxidative burst activity between the
2 groups suggests that the difference stems from the effect of
nicotinamide treatment.
Nicotinamide supresses PARP activity, which leads to de-
creased consumption of NAD, the substrate for PARP [9, 10].
NADP differs from NAD only by phosphorylation of the C-2 
OHgroupontheadenosylmoeity.Ithasbeenshownthatnicoti-
namideincreasesNAD+NADHcontentofbetacellsandcoun-
teracts the fall of superoxide dismutase level in diabetic NOD
mice [11], which may possibly be related to increased NAD
content. The drug may restore the impaired oxidative burst ca-
pacity of neutrophils in diabetic patients, also by increasing the
NADP content and by increasing the NADH consumption of
theenzymeandNADPHoxidaseactivityofthecell.Thiseffect
may result in increased H2O2 synthesis and production of other
more potent oxidizing radicals, such as oxidized halogens [15],
and increase respiratory burst potential following nicotinamide
treatment.
Most commonly observed side effects of nicotinamide are
nausea and vomiting. It has been reported that 48% of patients
taking 60 mg/kg nicotinamide experienced nausea and 32%
vomitting[16].Ruddockandcolleaguesshowedthatinisolated
rat ileum, nicotinamide reduces the peristalsis by interaction
with smooth muscle cells in a dose-dependent manner, which
maybeareasonforthesesymptoms[17].Inourstudy,only25%
of patients had nausea without vomiting and none discontinued
treatment because of side effects.
Although the data showed negative effects of nicotinamide
on insulin resistance [18], the nicotinamide group in the
study showed no deterioration of metabolic control during the
study.
In conclusion, neutrophil phagocytosis and respiratory burst
capacity are impaired in poorly controlled diabetic patients as
compared to healthy subjects and the differences in respiratory
burst activity were signiﬁcant between 2 groups. Nicotinamide
administration at 50 mg/kg/day resulted in signiﬁcant differ-
ences in respiratory burst activity at 30 and 45 minutes inde-
pendent of blood glucose control. This ﬁnding may be due to
nicotinamideeffect,whichneedsbeconﬁrmedwithlargerstud-
ies.Impairedneutrophilfunctionsmayaggravatevariousinfec-
tionsinpatientswithDMandbloodglucoseregulationisanim-
portant target of treatment to improve neutrophil functions [6].
Nicotinamide treatment may also be of value as an adjunctive
therapy.
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